ArticleFrontiers in immunology2021
Immune Microenvironment and Response in Prostate Cancer Using Large Population Cohorts.
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Article
- Cuprotosis-related gene subtypes, prognostic modeling, and tumor microenvironment remodeling in breast cancer.Translational cancer research · 2026Article
- NKAIN1 expression relates to the immune evasion and prognosis of gastric cancer.Scientific reports · 2025Article
- Brevilin A Inhibits Prostate Cancer Progression by Decreasing PAX5-Activated SOX4.Molecular biotechnology · 2025Article
- Precision Targeting in Metastatic Prostate Cancer: Molecular Insights to Therapeutic Frontiers.Biomolecules · 2025Review
- Acetyltransferase NAT10 promotes an immunosuppressive microenvironment by modulating CD8Molecular biomedicine · 2024Article
- Application of large-scale and multicohort plasma proteomics data to discover novel causal proteins in gastric cancer.Discover oncology · 2024Article
- A graph self-supervised residual learning framework for domain identification and data integration of spatial transcriptomics.Communications biology · 2024Article
- Development and Optimization of a Subtraction-Normalized Immunocyte Profiling Signature for Prostate Cancer Active Surveillance Risk Stratification.The Journal of urology · 2024Article
- Ensemble learning-based gene signature and risk model for predicting prognosis of triple-negative breast cancer.Functional & integrative genomics · 2023Article
- Research into the characteristic molecules significantly affecting liver cancer immunotherapy.Frontiers in immunology · 2023Article
- Comprehensive Analysis Based on the Cancer Immunotherapy and Immune Activation of Gastric Cancer Patients.Genetics research · 2023Article
- Comprehensive Explorations of CCL28 in Lung Adenocarcinoma Immunotherapy and Experimental Validation.Journal of inflammation research · 2023Article
- Identification of a Five Immune Term Signature for Prognosis and Therapy Options (Immunotherapy versus Targeted Therapy) for Patients with Hepatocellular Carcinoma.Computational and mathematical methods in medicine · 2023Article
- An epithelial-mesenchymal transition-related mRNA signature associated with the prognosis, immune infiltration and therapeutic response of colon adenocarcinoma.Pathology oncology research : POR · 2023Article
- Modelling aggressive prostate cancers of young men in immune-competent mice, driven by isogenic Trp53 alterations and Pten loss.Cell death & disease · 2022Article
- Prognostic Risk Signature and Comprehensive Analyses of Endoplasmic Reticulum Stress-Related Genes in Lung Adenocarcinoma.Journal of immunology research · 2022Article
- Sphingolipid metabolism is associated with osteosarcoma metastasis and prognosis: Evidence from interaction analysis.Frontiers in endocrinology · 2022Article
- Exploration of the underlying biological differences and targets in ovarian cancer patients with diverse immunotherapy response.Frontiers in immunology · 2022Article
- Establishment and Validation of a Machine Learning Prediction Model Based on Big Data for Predicting the Risk of Bone Metastasis in Renal Cell Carcinoma Patients.Computational and mathematical methods in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune microenvironment of prostate cancer (PCa) is implicated in disease progression. However, previous studies have not fully explored PCa immune microenvironment. This study used ssGSEA algorithm to explore expression levels of 53 immune terms in a combined PCa cohort (eight cohorts; 1,597 samples). The top 10 immune terms were selected based on the random forest analysis and used for immune-related risk score (IRS) calculation. Furthermore, we explored differences in clinical and genomic features between high and low IRS groups. An IRS signature based on the 10 immune terms showed high prediction potential for PCa prognosis. Patients in the high IRS group showed significantly higher percentage of immunotherapy response factors, implying that IRS is effective in predicting immunotherapy response rate. Furthermore, consensus clustering was performed to separate the population into three IRSclusters with different clinical outcomes. Patients in IRScluster3 showed the worst prognosis and highest immunotherapy response rate. On the other hand, patients in IRScluster2 showed better prognosis and low immunotherapy response rate. In addition,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.